Viatris (VTRS) Net Equity Issued and Repurchased (2022 - 2026)
Viatris (VTRS) posted Net Equity Issued and Repurchased of $700000.0 for Q2 2026, up 40.0% on a QoQ basis from $500000.0 in Q1 2026, and little changed year-over-year from $700000.0 in Q2 2025.
Powered by 
Analysis
Viatris (VTRS) Net Equity Issued and Repurchased (2022 - 2026) Analysis & Trends
Viatris has reported Net Equity Issued and Repurchased for 5 years, with the latest figure at $700000.0 in Q2 2026.
- On a quarterly basis, Net Equity Issued and Repurchased changed 0.0% year-over-year to $700000.0 in Q2 2026; TTM through Jun 2026 was $2.5 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.6 million, up 4.0% from the prior year.
- Net Equity Issued and Repurchased was $700000.0 for Q2 2026 at Viatris, up from $500000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $1.8 million in Q3 2022, with the low at $500000.0 in Q1 2026.
- Average Net Equity Issued and Repurchased over 5 years is $747058.8, with a median of $700000.0 recorded in 2022.
- The sharpest annual moves came in 2023 and 2025: Net Equity Issued and Repurchased plunged 55.56% in 2023, then advanced 16.67% in 2025.
- Over 5 years, Net Equity Issued and Repurchased stood at $800000.0 in 2022, then slipped by 25.0% to $600000.0 in 2023, then changed by 0.0% to $600000.0 in 2024, then changed by 0.0% to $600000.0 in 2025, then advanced by 16.67% to $700000.0 in 2026.
- The last three Net Equity Issued and Repurchased figures came in at $700000.0 (Q2 2026), $500000.0 (Q1 2026), and $600000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 700,000.00 |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | - |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | - |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | - |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 700,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 700,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 600,000.00 |
| Dec 31, 2023 | 600,000.00 |
| Sep 30, 2023 | 800,000.00 |
| Jun 30, 2023 | 800,000.00 |
| Mar 31, 2023 | 900,000.00 |
| Dec 31, 2022 | 800,000.00 |
| Sep 30, 2022 | 1.80 Mn |
| Jun 30, 2022 | 700,000.00 |